Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Esophageal Cancer | Research

MUC13 promotes the development of esophageal cancer by upregulating the expression of o-glycan process-related molecules

Authors: Yi Han, Gang Chen, Shiyu Liu, Guangqing Zhou, Xinxin Xu, Haihan Zhang, Zhentao Li, Chuannan Wu, Yulan Liu, Kai Fang, Guangxia Chen

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Background

Esophageal cancer is one of the most common malignant tumors in the world, which is characterized by poor prognosis, aggressiveness, and poor survival. Mucin 13 (MUC13) is a member of the membrane-bound mucin and located on chromosome 3q21.2 and consists of α and β subunits. It has been found that MUC13 is overexpressed in a variety of tumor cells and acts a vital role in the invasiveness and malignant progression of several types of tumors. However, the role and regulatory mechanism of MUC13 in the progression of esophageal cancer remain unclear.

Methods

The expression level of MUC13 was detected in 15 esophageal cancer tissues and 15 pairs of adjacent nontumor tissues by immunohistochemistry (IHC). In addition, the expression of MUC13 mRNA level in human esophageal cancer cell lines (EC9706 and ECA109 and TE-1) was measured by qRT-PCR. In vitro, after silencing MUC13 with lentiviral interference technology, CCK8 assay, clone formation assay, and flow cytometry were applied to investigate the proliferation activity, clone formation ability and anti-apoptosis ability of EC9706 and ECA109 cells. The tumor xenograft growth assay was used to confirm the influence of MUC13 knockdown on the growth of esophageal tumors in vivo. The qRT-PCR assay and western blot experiments were taken to study the mechanism of MUC13 regulating the proproliferation and antiapoptotic of esophageal cancer.

Results

The results showed that MUC13 was overexpressed in esophageal cancer tissues and cell lines (EC9706 and ECA109 and TE-1), especially in EC9706 and ECA109 cells, but low expressed in human esophageal epithelial cell line (HEEC). Next, silencing MUC13 inhibits proliferation, blocks cell cycle progression, and promotes cell apoptosis in vitro, and restrains the growth of esophageal cancer tissues in vivo. Finally, MUC13 affects the proproliferation and antiapoptotic by regulating the expression of GLANT14, MUC3A, MUC1, MUC12, and MUC4 that closely related to O-glycan process.

Conclusions

This study proved that MUC13 is an important molecule that regulates the O-glycan process and then affects the progress of esophageal cancer. MUC13 may be a novel therapeutic target for patients with esophageal cancer.
Appendix
Available only for authorised users
Literature
1.
Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2018;41(3):210–5.CrossRefPubMed
2.
Inoue M, Shimizu Y, Ishikawa M, Abiko S, Shimoda Y, Tanaka I, et al. Relationships of early esophageal cancer with human papillomavirus and alcohol metabolism. World J Gastroenterol. 2020;26(39):6047–56.CrossRefPubMedPubMedCentral
3.
di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology. 2018;154(2):421–36.CrossRefPubMed
4.
Borggreve AS, Kingma BF, Domrachev SA, Koshkin MA, Ruurda JP, van Hillegersberg R, et al. Surgical treatment of esophageal cancer in the era of multimodality management. Ann NY Acad Sci. 2018;1434(1):192–209.CrossRefPubMed
5.
Short MW, Burgers KG, Fry VT. Esophageal Cancer. Am Fam Physician. 2017;95(1):22–8.PubMed
6.
Sheng YH, Wong KY, Seim I, Wang R, He Y, Wu A, et al. MUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity. Oncogene. 2019;38(48):7294–310.CrossRefPubMed
7.
Kumari S, Khan S, Gupta SC, Kashyap VK, Yallapu MM, Chauhan SC, et al. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. Oncogenesis. 2018;7(2):19.CrossRefPubMedPubMedCentral
8.
Massey AE, Doxtater KA, Yallapu MM, Chauhan SC. Biophysical changes caused by altered MUC13 expression in pancreatic cancer cells. Micron. 2020;130: 102822.CrossRefPubMedPubMedCentral
9.
Tiemin P, Fanzheng M, Peng X, Jihua H, Ruipeng S, Yaliang L, et al. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. J Hepatol. 2020;72(4):761–73.CrossRefPubMed
10.
Stiles ZE, Khan S, Patton KT, Jaggi M, Behrman SW, Chauhan SC. Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions. HPB. 2019;21(1):87–95.CrossRefPubMed
11.
Gupta BK, Maher DM, Ebeling MC, Stephenson PD, Puumala SE, Koch MR, et al. Functions and regulation of MUC13 mucin in colon cancer cells. J Gastroenterol. 2014;49(10):1378–91.CrossRefPubMed
12.
He L, Qu L, Wei L, Chen Y, Suo J. Reduction of miR-132-3p contributes to gastric cancer proliferation by targeting MUC13. Mol Med Rep. 2017;15(5):3055–61.CrossRefPubMedPubMedCentral
13.
Li P, Wang H, Hou M, Li D, Bai H. Upstream stimulating factor1 (USF1) enhances the proliferation of glioblastoma stem cells mainly by activating the transcription of mucin13 (MUC13). Pharmazie. 2017;72(2):98–102.PubMed
14.
Chauhan SC, Vannatta K, Ebeling MC, Vinayek N, Watanabe A, Pandey KK, et al. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer Res. 2009;69(3):765–74.CrossRefPubMed
15.
Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, et al. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clin Chem Lab Med. 2018;56(11):1945–53.CrossRefPubMed
16.
Liu F, Fu J, Bergstrom K, Shan X, McDaniel JM, McGee S, et al. Core 1-derived mucin-type O-glycosylation protects against spontaneous gastritis and gastric cancer. J Exp Med. 2020;217(1): e20182325.CrossRefPubMed
17.
Ye J, Wei X, Shang Y, Pan Q, Yang M, Tian Y, et al. Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity. Oncogene. 2017;36(46):6391–407.CrossRefPubMed
18.
Yamanoi K, Ishii K, Tsukamoto M, Asaka S, Nakayama J. Gastric gland mucin-specific O-glycan expression decreases as tumor cells progress from lobular endocervical gland hyperplasia to cervical mucinous carcinoma, gastric type. Virchows Arch. 2018;473(3):305–11.CrossRefPubMed
19.
Wang H, Shen L, Lin Y, Shi Q, Yang Y, Chen K. The expression and prognostic significance of Mucin 13 and Mucin 20 in esophageal squamous cell carcinoma. J Cancer Res Ther. 2015;11(Suppl 1):C74–9.PubMed
20.
Shen LY, Wang H, Dong B, Yan WP, Lin Y, Shi Q, et al. Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling. Oncotarget. 2016;7(4):4531–41.CrossRefPubMed
21.
Domper Arnal MJ, Ferrández Arenas Á, Lanas AÁ. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–43.CrossRefPubMedPubMedCentral
22.
Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg. 2013;61(6):330–5.CrossRefPubMed
23.
24.
Dai Y, Liu L, Zeng T, Liang JZ, Song Y, Chen K, et al. Overexpression of MUC13, a poor prognostic predictor, promotes cell growth by activating wnt signaling in hepatocellular carcinoma. Am J Pathol. 2018;188(2):378–91.CrossRefPubMed
25.
Freitas D, Campos D, Gomes J, Pinto F, Macedo JA, Matos R, et al. O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype. EBioMedicine. 2019;40:349–62.CrossRefPubMedPubMedCentral
26.
Chia J, Goh G, Bard F. Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives. Biochim Biophys Acta. 2016;1860(8):1623–39.CrossRefPubMed
27.
Cervoni GE, Cheng JJ, Stackhouse KA, Heimburg-Molinaro J, Cummings RD. O-glycan recognition and function in mice and human cancers. Biochem J. 2020;477(8):1541–64.CrossRefPubMed
28.
Gautam SK, Kumar S, Dam V, Ghersi D, Jain M, Batra SK. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy. Semin Immunol. 2020;47: 101391.CrossRefPubMedPubMedCentral
29.
Gao SL, Yin R, Zhang LF, Wang SM, Chen JS, Wu XY, et al. The oncogenic role of MUC12 in RCC progression depends on c-Jun/TGF-β signalling. J Cell Mol Med. 2020;24(15):8789–802.CrossRefPubMedPubMedCentral
30.
Huang GTQ, Bi YN, Cui Z, Guan JP, Huang YC. MUC1 confers radioresistance in head and neck squamous cell carcinoma (HNSCC) cells. Bioengineered. 2020;11(1):769–78.CrossRefPubMedPubMedCentral
31.
Metadata
Title
MUC13 promotes the development of esophageal cancer by upregulating the expression of o-glycan process-related molecules
Authors
Yi Han
Gang Chen
Shiyu Liu
Guangqing Zhou
Xinxin Xu
Haihan Zhang
Zhentao Li
Chuannan Wu
Yulan Liu
Kai Fang
Guangxia Chen
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00713-3

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes

Research

Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy

Research

Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy

Research

Comparison of two high dose rate intracavitary brachytherapy regimens in treatment of cervical cancer: a preliminary report

Research

Cardiac dose in the treatment of synchronous bilateral breast cancer patients between three different radiotherapy techniques (VMAT, IMRT, and 3D CRT)

Research

Nonconvulsive status epilepticus characteristics in glioma patients: a retrospective study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits